IV infusion of opebacan to replace endogenous BPI during the peritransplant period will result in the reduction of LPS-induced inflammatory sequelae, in particular aGvHD, in patients undergoing allogeneic HSCT.~The rationale for using opebacan in patients undergoing myeloablative regimens and HSCT is based on the following:~Endotoxemia has been demonstrated to play a central pathophysiologic role as a trigger of aGvHD in animal models.~Endotoxemia following HSCT is associated with inflammatory conditions (such as inflammatory cytokine release) that have been demonstrated in humans to be associated with organ damage and increased morbidity and mortality.~Endotoxemia and LBP elevation have been demonstrated in humans undergoing ablative HSCT.~Chemotherapy-induced neutropenia results in a deficiency of endogenous BPI levels.~The timing of the endotoxemic insult is predictable (i.e., subsequent to myeloablative chemotherapy and radiotherapy).~The return to normal neutrophil levels is not immediate and takes one week to several weeks.~Well established laboratory techniques for surrogate markers related to LPS presence and its activities can facilitate the evaluation of molecules designed to inhibit or antagonize LPS and its effects.~The objectives of this study are as follows:~To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation~To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation~To determine if IV administration of opebacan is associated with changes in biological markers for inflammation~To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD
The objectives of this study are as follows:~To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation~To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation~To determine if IV administration of opebacan is associated with changes in biological markers for inflammation~To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD